通过将植物性饮食纳入炎症性肠道疾病的治疗进步
Mitsuro Chiba1, Tsuyotoshi Tsuji1, Masafumi Komatsu1
1Division of Gastroenterology, Akita City Hospital, Akita, Japan.
Translational gastroenterology and hepatology
|November 29, 2023
概括
西方饮食是炎症性肠病 (IBD) 的关键环境因素. 植物性饮食 (PBD) 与因弗利西马布 (Infliximab) 结合,显示出对克罗恩氏病的优异结果.
科学领域:
- 胃肠病学和营养科学 胃肠病学和营养科学
- 微生物组研究 微生物组研究
- 免疫学 免疫学 免疫学
背景情况:
- 炎症性肠病 (IBD) 缺乏公认的环境因素,尽管发病率与饮食变化相关.
- 目前的西方饮食被认为是危险因素,促进肠道失调和炎症.
- 标准疗法,甚至是均衡的饮食,往往无法预防复发,特别是在克罗恩病 (CD).
研究的目的:
- 为了确定IBD无处不在的环境因素.
- 评估植物性饮食 (PBD) 作为对抗西方饮食在IBD管理中的有效性.
- 评估PBD和infliximab作为一线治疗的联合作用.
主要方法:
- 一种植物性饮食 (乳酸卵性半素食) 被开发和实施.
- 患有性结肠炎 (UC) 和克罗恩病 (CD) 的患者接受了住院PBD治疗.
- 作为一线治疗 (IPF) 的一部分,Infliximab被用于所有CD患者和严重UC病例.
主要成果:
- IPF治疗实现了高缓解率:96%的CD和76%的严重UC.
- 单纯的PBD在三分之一的轻度UC病例中引起了缓解.
- 在10年的随访中,52%的CD患者在没有生物药物或免疫抑制剂的情况下仍然没有复发.
结论:
- 目前的西方饮食被认为是驱动IBD的无处不在的环境因素.
- PBD是一种非常有效的饮食干预措施,用于管理UC和CD.
- IPF疗法提供了一个有前途的策略,以克服IBD中对生物药物的初级不反应.
相关概念视频
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
335
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
335
Inflammatory Bowel Disease IV: Pharmacological Management
130
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
130
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
168
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
168
Inflammatory Bowel Disease V: Surgical Management
148
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
148
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
121
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
121
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
143
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
143


